Abstract 4694: Evaluation of tumor-associated antigen expression with the MACSima^TMhigh-content imaging platform

Immune contexture analysis in immuno‐oncology: applications and challenges of multiplex fluorescent immunohistochemistry

“…However, this process can be very labour intensive because of the need to stain and image each biomarker sequentially, 21,26 resulting in prolonged turnaround time and potential changes of the tissue morphology and antigenicity because of repetitive exposure to the dye bleaching and/or antibody stripping conditions. 21 Emerging antibody-based imaging techniques, 27,28 such as imaging mass cytometry (IMC), 29 multiplexed ion beam imaging (MIBI), 30 Nanostring GeoMx â , 31,32 CODEX âTM , 33 InSituPlex â , 34,35 and MACSima TM36,37 can further produce omics-like data through quantification of up to 40 markers. However, these technologies require longer measurement time, limiting the number of region of interests and size of the tissue that can be imaged (Table 5).…”

“…Some of these platforms also provide fully integrated image acquisition and multiplexed data analytics that may overcome current obstacles of integration and interoperability. For example, Nanostring's GeoMx â Digital Spatial Profiling (DSP), 31,32 Akoya Biosciences CODEX â , 33 Miltenybiotec's MACSima TM , 36,37 and IONpath's MIBIscope TM30 are some of the emerging platforms that offer end-to-end solutions from highly multiplexed staining and image acquisition to a fully integrated high-plex data analytics. Advances in fully integrated multiplexed methodologies and tissue-based image analysis solutions that can integrate with clinical digital pathology workflow are critical for delivering better diagnostic and treatment decision to cancer patients.…”

The prospects of single‐cell analysis in autoimmunity

“…More than hundred proteins can be imaged in a single run by cycling of each marker. 124 These methods may have importance particularly in autoimmunity research to portray the interactions between the immune system and the affected tissues (Table 3).…”